Video: EGFR-Mutant NSCLC: Is There A Role For Combined Therapy?
—Laurie Matt-Amaral, MD, of Cleveland Clinic, discusses how combining therapies for non-small cell lung cancer patients can complicate their treatment. (2:26)
Published:
.jpg)
Measures of systemic inflammation have been developed as prognostic indexes, but few studies have examined the association between these indexes and NSCLC postsurgical outcomes. Researchers in the U.K. attempted to set the record straight.
Researchers in Michigan recently reported several predictors of esophagitis, a common adverse event during radiation therapy for locally advanced NSCLC. Some of these factors may seem familiar, others may not. Read on to learn the details.
Among lung cancer care teams, an understanding of the TNM-8 clinical staging system is critical for prognosis and treatment selection. A newly published report lays out the key criteria, special considerations, and some potential future revisions.